John Marshall, MD

Articles

Clinical Considerations for 2L Treatment Sequencing in mCRC

June 26th 2024

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

Overview of Molecular Testing and Barriers in mCRC

June 26th 2024

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.

Exploring Newly Released Data in GU and GI Cancers: Drs Grivas and Marshall

June 3rd 2024

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Insights on Existing and Prospective Second-line Treatment Strategies for Patients With ESCC

June 14th 2022

Thoughtful discussion of existing and emerging second-line treatment options for patients with metastatic ESCC

First-line Treatment Approaches and Considerations for Patients With Metastatic ESCC

June 14th 2022

Focusing on metastatic ESCC, John Marshall, MD, discusses selecting appropriate first-line treatment strategies for patients.

Trends and Disparities in Treatment Approaches for Patients With Locoregional ESCC

June 8th 2022

Shared insights on contemporary approaches to treating localized ESCC and existing racial disparities in treatment.

A Survey of Patient Presentation, Testing, and Diagnosis in ESCC

June 8th 2022

Broad discussion from expert John Marshall, MD, on the current standards of diagnosis care in esophageal squamous cell carcinoma (ESCC).

Dr. Marshall on the Potential Utility of Trastuzumab Deruxtecan in HER2+ Gastric Cancer

November 8th 2021

John L. Marshall, MD, discusses the potential utility of trastuzumab deruxtecan in HER2-positive gastric cancer.

Dr. Marshall on Early Data With Trastuzumab Deruxtecan in HER2+ CRC

May 6th 2021

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.

Dr. Marshall on the Emergence of Novel HER2-Targeted Agents in CRC

January 28th 2021

John L. Marshall, MD, discusses the emergence of novel HER2-targeted therapies for patients with colorectal cancer.

Dr. Marshall on Changes With Adjuvant Treatment in CRC

January 25th 2021

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

Dr. Marshall on Challenges With Sequencing in CRC

October 15th 2020

John L. Marshall, MD, discusses ​sequencing challenges in colorectal cancer.

Dr. Marshall on the Importance of Molecular Testing in Gastrointestinal Cancers

July 13th 2020

John L. Marshall, MD, discusses the importance of molecular testing in gastrointestinal cancers.

Dr. John Marshall on Steps to Finding a Cure for Colorectal Cancer

December 21st 2015

John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.

Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer

November 10th 2015

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.